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The characterization of leukemic stem cells (LSC) 
and their potential differences as compared to normal 
hematopoietic stem cells (HSC) are important for un-
derstanding the process of malignant transformation. 
The multistage process of hematopoiesis result-
ing in the appearance of the mature cells of the pe-
ripheral blood (erythrocytes, leukocytes, platelets) 
is maintained by HSC. The existence of the common 
multipotent hematopoietic stem cell (MHSC) is a fun-
damental principle of the modern unipotent scheme of 
hematopoiesis [1–3]. MHSCs possess the self-renewal 
abilities, high proliferative potential and are capable for 
maintaining myelo- and lymphopoiesis. 
As early as in 1961, Till and McCulloch [4]  elaborated 
the technique for cloning the hematopoietic cells in the 
spleen of lethally irradiated mouse and gave the first 
experimental evidence that HSC in fact exist. Since that 
time, the particular progress has been made in defining 
the role of factors produced by stromal microenvironment 
(cytokines and interleukins) in controlling proliferation and 
differentiation of hematopoietic progenitor cells.
The HSC population is a heterogeneous one subdivid-
ing into long-term HSCs (LT-HSCs) and short-term HSCs 
(ST-HSCs). While ST-HSCs have limited self-renewal ca-
pacity giving rise to myeloid and lymphoid lineages within 
about 8 weeks, LT-HSCs are capable of self-renewal 
giving rise to long-term bone marrow culture capable of 
differentiating to myeloid and lymphoid lineages. HSC 
gives rise to oligolineage-restricted progenitors with 
limited ability of self-renewal: the common progenitor 
cell of myelopoiesis and the common progenitor cell of 
lymphopoiesis. The progenitor cells in turn give rise to 
the cells with most limited differentiation potential and 
finally to the functionally mature cells. 
In the generally recognized scheme of the he-
matopoiesis [2], HSC as well as progenitor cells class 
II and III were depicted as the empty circles. Chertkov 
and Vorobiov [3] in their scheme of the hematopoiesis 
predicted that depending on the phase of cell cycle 
HSC and progenitor cells possess the cytomorphologi-
cal features of blasts or lymphocyte-like cells.
Cytomorphological and cytochemical features 
of HSC and hematopoietic progenitors. Besides 
the analysis of cell population in splenic colonies 
develo ped in the lethally irradiated mouse upon graf-
ting the bone marrow cells and the study of the least 
differentia ted cells in granulocytic and monocytic-
macrophage colonies and clusters in vitro, another 
approach turned out to be promising.
Prof. Butenko in the monograph “Hematopoietic stem 
cells and leukemia” published in Ukraine [5] presented 
the cytomorphological features of the presumable “can-
didates” for hematopoietic stem cells. In R.E. Kavetsky 
Institute of Oncology Problems (Kyiv, Ukraine), the cyto-
logical and cytochemical study of HSC and progenitor 
cells has been performed. In particular, the early stages 
of the embryonic hematopoie sis in human and mouse 
were studied, especially the early hematopoietic cells 
in the yolk sac, which later migrate to liver and populate 
bone marrow, spleen, thymus, and lymph nodes [6].
Earlier we have demonstrated that the hematopoietic 
progenitor cells of classes II–III (according to Chertkov and 
Vorobiov’s scheme of hematopoiesis) regarded earlier as 
morphologically non-distinguishable turned out to possess 
some marker cytochemical features pertinent to more ma-
ture cells of granulocytic lineage (positive peroxidase and 
chloracetate esterase activity); monocytic-macrophage 
lineage (high non-specific alpha-naphtyl acetate esterase 
activity); megakaryocytic lineage (positive acetylcholin es-
terase activity) and T-lymphocyte lineage (granular or dot-
like acid phosphatase reaction) [6]. Our findings together 
with the results of several biochemical studies performed in 
former USSR may be regarded as the retrospective ratio-
nale substantiating the use of the cytochemical techniques 
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for delineating the various forms and cytological variants 
of the acute myeloid and lymphoid leukemias origi nating 
from the transformation and the clonal proliferation of 
various types of the hematopoietic progenitor cells.
Recently, the immunophenotypic profile of HSC and 
hematopoietic progenitor cells has been extensively 
studied. In particular, the phenotype of the pluripotent 
stem cell is now delineated as CD34+, CD90+, CD172a+, 
CD173+, CD174+, CD175+, CD176+, CD224+, CD227+, 
CD239+, HLA-DR+. Accordingly, the phenotype of my e -
lo id stem cells is CD33+, CD34+, CD38+, CD117+, CD123+, 
CD133+, HLA-DR+, TdT+/–, CD13+/–, CD7+/–, CD230+; the 
phenotype of lymphoid stem cells is CD10+, CD34+, 
CD38+, CD117+/–, CD124+, CD127+, HLA-DR+, TdT+. 
In fact, only identified markers are given in the listed 
phenotypes above, and the exact sets of the phenotypic 
markers of HSC and hematopoietic progenitor cells in 
all lineages are still to be elucidated [7, 11–13].
Leukemic stem cells. Leukemias as well as other 
cancers represent the clonal processes. The leukemic 
cells infiltrating the bone marrow as well as the leuke-
mic cells detected in the blood and in the organs of the 
body are the descendents of the single cell undergo-
ing the malignant transformation (HSC or committed 
progenitor cell). There are many functional similari-
ties between the LSC and solid tumor stem cells. The 
milestones of the study of HSC and cancer stem cells 
are summarized chronologically in Table 1.
The experimental evidence for the existence of 
clonogenic or LSC was obtained in 1997 in hete-
rotransplantation experiments in SCID mouse with 
severe combined immunodeficiency (lack of В- and 
Т-cells) and NOD/SCID (nonobese diabetic x SCID) 
mouse (in addition to SCID mouse NK cells are la cking, 
the macrophage activity is not detected neither the 
complement activation) [12]. 
Table 1. Milestones of the studies developing the concept of cancer stem cell
1961 Experimental evidence of polypotent 
hematopoietic stem cells
Till and McCulloch, 1961 [4]
1967– 
1981
Evidence of CML and AML clonality Fialkow et al., 1967; 
 Fialkow, 1981 [8, 9]
1972– 
1973
Elaboration of modern unipotent 
scheme of hematopoiesis
Mathe et al., 1972; Chertkov 
and Vorobiov, 1973 [2, 3]
1975– 
1990
The technology for production of mono-
clonal antibodies against lineage-specific 
and differentiation antigens of leukocytes
Kohler, Milstein, 1975 [10]
1988 Use of mouse with severe combined 
immunodeficiency (SCID) for study-
ing human hematopoietic cells
Weissman (ref. Passegue 
et al., 2003) [11]
1989– 
1994
Use of SCID mouse and mouse with 
SCID and non-obese diabetes (NOD/
SCID) for studying leukemic cells
Dick et al., 1996 [12]
Passegue et al., 2003 [11]
Huntly, Gilliland, 2005 [13]
1997 Identification of leukemic stem cell Dick et al., 1996 [12]
2003 Identification of stem cell in breast cancer Al-Hajj et al., 2003 [14]
2004 Identification of human brain tumor 
initiating cells
Singh et al., 2004 [15]
2005 Prostate cancer stem cells Collins and Maitland, 2005 [16]
2005 Epithelial ovarian cancer stem cells Bapat et al., 2005 [17]
2005 Osteogenic sarcoma stem cells Gibbs et al., 2005 [18]
2005 Melanoma stem cells Fang et al., 2005 [19]
2007 Neuroblastoma stem cells Ross, Spengler, 2007 [20]
2008 Lung cancer stem cells Eramo et al., 2008 [21]
Upon transplantation of leukemic cells from bone 
marrow and peripheral blood of AML patients (regard-
less FAB type), most leukemic blasts are not capable to 
proliferate. Only a small subset of leukemic cells in the 
Table 2. Markers of normal and transformed hematopoietic stem cells and progenitor cells.
Antigen Structure and function Normal expression Expression in hematoblastoses
CD19 Belongs to IgSF family, takes part in signal 
transduction controlling B-cell activation 
and differentiation
B-cell progenitors; mature B-cells B-cell leukemias and lymphomas
CD34 Sialomucin involved in intercellular adhesion Hematopoietic stem cells and progenitor cells AML and ALL; leukemic stem cells
CD38 ADP-ribosyl cyclase; takes part in the 
control of cell activation and proliferation
Progenitor cells of myelopoiesis, T and B cells, 
monocytes, activated T and B cells, plasma cells
Non-clonogenic cells in AML, cells in 
multiple myeloma
CD45RA Common leukocyte antigen, regulator 
of leukocyte activation
В cells, activated T cells, monocytes, macrophages B cell leukemia
CD90 (Thy-1) Participate in differentiation of HSC 
and neuronal cells
HSC, Т cells, fibroblasts, stromal cells Blasts in several forms of AML, rare 
cases of ALL
CD123 (IL-3Rα) α-subunit of IL-3 receptor Progenitor cells, endothelial cells, stromal cells Blasts in AML; leukemic stem cells
HLA-DR Histocompatibility antigen class II В cells, antigen-presenting cells, progenitor myeloid 
cells
Blasts in various forms of AML except 
for AML M3, most B cell tumors
CD172a SIRP-1α, belongs to Ig superfamily CD34+ HSC, hemopoietic progenitor cells, monocytes, 
macrophages, granulocytes, dendritic cells
–*
CD173 Antigen H (glycotop Fucα1−2Galβ1-4GlcNAcβ), 
progenitor of group A and B antigens
Subpopulation of CD34+ HSC, erythrocytes, 
platelets, endothelial cells
–*
CD174 Lewis Y antigen Subpopulation of CD34+ HSC, new marker of 
hemopoietic progenitor cells, epithelial cells
–*
CD175 Tn antigen (epitope GalNAcα1-, O-linked 
with serine or threonine
Subpopulation of HSC, tumors of epithelial origin AML cell lines (HG-1a, HL-60), K-562, 
B-cell leukemia (REH, Nalm-6), T-cell 
leukemia (Jurkat)
CD176 TF antigen (epitope Gal β1-3GalNAcα1-, 
O-linked with serine or threonine
Subpopulation of HSC, different types of cancer cells –*
CD213a1 Low affinity receptor α1 IL-13 Hemopoietic progenitor cells, subpopulation of 
peripheral blood leukocytes, B-cells, monocytes, 
endothelial cells, fibroblasts
–*
CD224 Ectoenzyme γ-gluta myl transpeptidase HSC, subpopulation of B-cells, CD45RO+ T-cells, 
macrophages
–*
CD227 Polymorphic transmembrane epithelial 
mucine (MUC-1)
Subpopulation of HSC, B-cells, monocytes, follicular 
dendritic cells, glandular and tubular epithelial cells
–*
CD230 PrP-sialoglycoprotein Hemopoietic progenitor cells, lymphocytes, 
monocytes, neurons
–*
CD239 B-CAM glycoprotein, belongs to Ig 
superfamily
Subpopulation of HSC, erythrocytes, endothelial 
cells, basal membrane epithelial cells
–*
*Data on expression of CD172a, CD173, CD174, CD175, CD176, CD213a1, CD224, CD227, CD230, CD239 were not found in available literature.
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fraction of CD34+CD38– cells was capable of extensive 
proliferation (from 0.2 to 1%).
The recent data suggest that the majority of AML 
(except for AML M3) as well as CML develop as a result 
of mutations accumulated in HSC.
Several markers of normal HSC and progenitor 
cells are expressed also in leukemic cells. The data 
on the expression, structure, and function of several 
antigens expressing on the surface of HSC and pro-
genitor cells as compared with their expression in vari-
ous forms of the malignancies of hematopoietic and 
lymphoid tissues are summarized in Table 2.
The immunophenotype of MHSC and LSC in different 
leukemias was delineated [11, 12]. In particular, the im-
munophenotype of MHSC in normal hematopoiesis has 
been suggested as CD34+CD38–CD90+CD123–CD117+. 
The suggested immunophenotype of LSC in acute myelo-
genous leukemia is CD34+CD38–CD90–CD123+CD117–
CD71–HLA-DR–, while in acute lymphoblastic leukemia 
the suggested immunophenotype of LSC is CD34+CD38–
Lin–CD10–CD19–. Moreover, in contrast to the normal 
HSC, a universal phenotype for LSC may not exist, and 
patient-to-patient variations in cell surface antigen ex-
pression may be the rule.
Various cytological forms of acute myeloid leuke-
mia (M0–M7) are believed to originate from a hierarchy 
of leukemic stem cell classes that differ in self-renewal 
capacities, molecular and cellular features [12].
The results of our studies suggest that the standard 
panel for classification of acute leukemias [24] should be 
supplemented with several new markers allowing us to 
identify more precisely the different forms of leukemias 
being of the closely related origin, for example AML M6b 
(МPО–, HLA-DR+/–, CD34+, CD117–, CD71+, CD33–/+ and 
CD13–/+, CD36+) vs AML M7 (МPО–, HLA-DR+/–, CD34–/+, 
CD117–, CD71–/+, CD33+/– or CD13+/–, CD36+/–) (Table 3). 
We suggest the existence of the common bipotent LSC in 
AML M7 of low grade and AML M6b, which is analogous 
to precursor cell common for megakaryocytopoiesis 
and erythropoiesis. We have also found the similarity 
between the blast cells in pro-B-ALL [МPО-, HLA-DR+, 
CD34+ (less than 50% of cells), CD19+ and CD33– (or 
their co-expression), t (4;11), 11q23] and AML M5a 
[МPО–, HLA-DR+/–, CD34+/–, CD33+ and CD19– (or their 
co-expression), t (9;11), 11q23] (Table 4). The similarity 
of immunophenotype and cytogenetic abnormalities 
in blast cells in pro-B-ALL and AML M5a seems to be 
the hint explaining the cases of AML M5a as a recur-
rence of leukemia in children with originally diagnosed 
pro-B-ALL. Moreover, the common LSC for pro-B-ALL 
and AML M5a further suggest the analogous precursor 
cell for the normal hematopoiesis. Therefore, the modern 
concept of LSC allows one to analyze in more depth the 
mechanisms of leukemic transformation of target cells 
in acute leukemias of the closely related origin such as 
AML M6 vs AML M7; AML M5a vs pro-B-ALL. 
Based on the consistency of CD34+CD38– cell surface 
immunophenotype in different AML subtypes except for 
M3 and their similarity to the phenotype of normal HSC, a 
model of leukemogenesis was proposed [22] suggesting 
that the transformation genetic events occur in primitive 
stem cells. According to the alternative point of view, that 
cells of origin for AML M0–M7 are the lineage committed 
hematopoietic progenitors [23, 24]. As was stated by 
Weissman [11], the mechanisms of leukemic transforma-
tion involve the increased cell survival, the increased proli-
ferative potential, the increased self-renewal capability, the 
genome instability, and the disordered differentiation.
Table 3. Immunophenotype of blasts in AML М6b and AML М7
Acute erythroleukemia (AML М6b) Acute megakaryoblastic leukemia (AML М7)
МPО– МPО–
HLA-DR+/– HLA-DR+/–
CD34+ CD34–/+
CD117– CD117–
CD71+ CD71+
CD33– and CD13– CD33+/– or CD13+/–
CD36+ CD36+
Table 4. Immunophenotype of blasts in pro-В-ALL and AML М5а
Pro-В-ALL AML М5а
MPO– MPO–
HLA-DR+ HLA-DR+
CD34+ (90–100% cells) CD34+/– (less than 50% cells)
CD19+CD33– (co-expression is 
possible)
CD33+CD19– (co-expression is 
possible)
t (4;11), 11q23 t (9;11), 11q23
The recent data on the presumptive target cells for 
leukemic transformations and the candidates LSC in 
various hematopoietic malignancies delineated in ac-
cordance with the recent WHO classification [25] are 
summarized in Table 5.
Table 5. Candidate LSC in the tumors of hematopoietic and lymphoid tissues [25]
Chronic myeloproliferative diseases
Chronic myelogenous leukemia Pluripotent bone marrow SC
Chronic eosinophilic leukemia Pluripotent SC in case of t (8;13); 
multipotent HSC or committed 
eosinophil precursor cell
Polycythemia vera Multipotent HSC
Chronic idiopathic myelofibrosis Multipotent HSC
Essential thrombocytemia Bone marrow SC with variable lineage 
potential
Myelodysplastic/myeloproliferative diseases
Chronic myelomonocytic leukemia HSC
Atypical chronic myeloid leukemia Bone marrow myeloid SC
Juvenile myelomonocytic leukemia Multipotent or pluripotent HSC
Myelodysplastic syndromes
Refractory anemia (RA) HSC
Refractory anemia with ringed 
sideroblasts (RARS)
HSC
Refractory cytopenia with 
multilineage dysplasia (RCMD)
Myeloid SC
Refractory anemia with excess 
blast (RAEB)
Myeloid SC
Unclassifiable Myeloid SC
Associated with del (5q)- HSC
Acute myeloid leukemias
AML with recurrent cytogenetic 
abnormalities
Myeloid SC with potential to 
granulocytic differentiation
AML with 11q23 (MLL) HSC with multilineage potential
AML with multilineage dysplasia HSC
Therapy-related AML HSC
AML not otherwise characterized
AML minimally differentiated and 
AML with maturation
Precursor HSC at early stage of 
myeloid differentiation
Acute myelomonocytic leukemia HSC with potential to differentiate into 
granulocytic and monocytic lineages
Acute monoblastic and monocytic 
leukemia
HSC with some commitment to 
monocytic differentiation
Acute erythroid leukemia Multipotent HSC with myeloid potential
Acute megakaryoblastic leukemia Precursor cell committed to mega karyo-
cytic and possibly erythroid differentiation
Acute lymphoblastic leukemias
Precursor B-lymphoblastic 
leukemia/lymphoma
Precursor B-lymphoblast
Precursor T-lymphoblastic 
leukemia/lymphoma
Precursor T-lymphoblast
Experimental Oncology 30, 102–105, 2008 (June) 105
CONCLUSION
The identification of LSC in specified types and vari-
ants of the diseases should be an important task in the 
routine diagnostic research in leukemia patients. The 
identification of LSC and gene expression in heteroge-
neous forms of hemoblastoses differed by cytological, 
cytochemical features as well as by immunophenotype 
is advantageous for studying in depth molecular and 
genetic mechanisms of leukemogenesis. LSC and 
not the usual blasts should be regarded as the major 
targets for the novel therapeutic modalities.
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ИзученИе морфоцИтохИмИческИх 
И ИммунофенотИпИческИх прИзнаков стволовых 
клеток прИ острых лейкозах
Иммунофенотипический профиль стволовых лейкемических клеток (СЛК) интенсивно изучают в ряде лабораторий мира. 
Результаты данного исследования подтверждают, что стандартная панель для классификации острых лейкозов (ОЛ) должна 
быть дополнена рядом новых маркеров. Это позволяет более точно идентифицировать близкие по происхождению формы 
ОЛ, например ОМЛ М6b и ОМЛ М7. Предполагается существование общей низкодифференцированной бипотентной ЛСК 
при ОМЛ М7 и ОМЛ М6b, подобной нормальной общей клетке-предшественнице мегакариоцитопоэза и эритропоэза. 
Установлено также сходство бластных клеток при про-В-ОЛЛ  с перестройкой хромосомного участка 11q23 и транслокацией 
(4;11) и бластных клеток при ОМЛ М5а c перестройкой того же хромосомного участка 11q23 и транслокацией (9;11). 
Подобное сходство иммунофенотипа и цитогенетических аномалий при указанных 2 формах ОЛ объясняет появление 
бластов с фенотипом ОМЛ М5а при рецидиве заболевания у детей, у которых ранее был диагностирован про-В-ОЛЛ.
Ключевые слова: стволовая лейкемическая клетка, острые лейкозы, классификация, иммунофенотип. 
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